Characterization of CD44v3-containing isoforms in head and neck cancer

Cancer Biology and Therapy

Volumn 5, Issue 9, 2006, Pages 1163-1168

  Reategui, Erika P ^c   De Mayolo, Adriana Antúnez ^c   Das, Parpha M ^c   Astor, Frank C ^a,c   Singal, Rakesh ^b,c,d   Hamilton, Kara L ^b,c   Goodwin, W Jarrard ^a,c   Carraway, Kermit L ^b,c   Franzmann, Elizabeth J ^a,c,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

CD44v; CD44v3; CD44v3 10; Head and neck squamous cell carcinoma

Indexed keywords

GLYCOPROTEIN; HERMES ANTIGEN; MESSENGER RNA;

ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; GEL ELECTROPHORESIS; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PURIFICATION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

EID: 33751111936     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.9.3065     Document Type: Article

References (30)

1. Muir C, Weiland L. Upper aerodigestive tract cancers. Cancer Suppl 1995; 75:147-53.
2. Parkin DM, Pisani P, Farlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827-41.
3. Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: When do the ends justify the means? Laryngoscope 2000; 110:S1-18.
4. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345:1890-900.
5. Naor D, Sionov RV, Ish-shalom D. CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997; 71:241-319.
6. Lokeshwar VB, Iida N, Bourguignon LYW. The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation. J Biol Chem 1996; 271:23853-64.
7. Brown TA, Bouchard T, St. John T, Wayner E, Carter WG. Human keratinocytes express a new CD44 core protein (CD44E) as a heparin-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 1991; 113:207-21.
8. Omary MB, Trowbridge IS, Letarte M, Kagnoff MF, Isacke CM. Structural heterogeneity of human Pgp-1 and its relationship with p85. Immunogenetics 1988; 27:460-4.
9. Trowbridge IS, Lesley J, Schulte R, Hyman R, Trotter J. Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues. Immunogenetics 1982; 15:299-312.
10. Bourguignon LYW, Iida N, Welsh CF, Zhu D, Krongrad A, Pasquale D. Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion, and tumor metastasis. J Neurooncol 1995; 26:201-8.
11. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signaling regulators. Nature Rev Mol Biol 2003; 4:33-45.
12. Franzmann EJ, Reategui EP, Carraway KL, Hamilton KL, Weed DT, Goodwin WJ. Salivary soluble CD44: A potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:735-9.
13. Lokeshwar VB, Bourguignon LYW. Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 and its biosynthetic precursors during T-lymphoma membrane biosynthesis. J Biol Chem 1991; 266:17983-9.
14. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci 1992; 89:12160-12164.
15. Weg-Remers S, Ponta H, Herrlich P, König H. Antagonistic signaling pathways regulate alternative splicing of CD44 in T cells. Ann NY Acad Sci 2002; 973:112-115.
16. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease progression. Lancet 1992; 340:1053-8.
17. Iida N, Bourguignon LYW. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995; 162:127-33.
18. Dall P, Heider KH, Sinn HP, Skroch-Angel P, Adolf G, Kaufmann M, Herrlich P, Ponta H. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995; 60:471-77.
19. Rodriguez C, Monges G, Rouanet P, Dutrillaux B, Lefrancois D, Theilett C. CD44 expression patterns in breast and colon tumors: A PCR-based study of splice variants. Int J Cancer 1995; 64:347-54.
20. Kaufmann M, Heider KH, Sinn HP, Von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345:615-9.
21. Kalomiris EL, Bourguignon LYW. Mouse T-lymphoma cells contain a transmembrane glycoprotein (GP85) which binds ankyrin. J Cell Biol 1988; 106:319-27.
22. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrilich P. A new variant of glycoprotein CD44 confer metastatic potential to rat carcinoma cells. Cell 1991; 65(1):13-24.
23. Jackson DG, Bell JI, Dickinson R, Timans J, Shields J, Whittle N. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol 1995; 128:673-85.
24. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G, Aruffo A. CD44 isoforms containing exon v3 are responsible for the presentation of heparin binding growth factor. J Cell Biol 1995; 128:687-98.
25. Barbour AP, Reeder JA, Walsh MD, Fawcett J, Antalis TM, Gotley DC. Expression of the CD44v2-10 isoform confers a metastatic phenotype: Importance of the heparan sulfate attachment site CD44v3. Cancer Res 2003; 63(4):887-92.
26. Franzmann JE, Weed DT, Civantos FJ, Goodwin WJ, Bourguignon LYW. A novel CD44v3 isoform is involved in head and neck squamous cell carcinoma progression. Otol H and N Surg 2001; 124(4):426-32.
27. Hudson D, Speight P, Watt F. Altered expression of CD44 isoforms in squamous cell carcinomas and cell lines derived from them. Int J Cancer 1996; 66:457-463.
28. Ferris RL, Xi L, Raja S, Hunt JL, Wang J, Gooding WE, Kelly L, Ching J, Luketich JD, Godfrey TE. Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck. Cancer Res 2005; 65:2147-56.
29. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, Simmons DL. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994; 54:4539-46.
30. Van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, Van den Brekel MW, Snow GB, Brakenhoff RH. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: A prospective study. Clin Cancer Res 2004; 10:3614-20.